Sumanta K. Pal, MD, FASCO, on Moving Forward with Cabozantinib as Treatment for Patients with RCC

Video

Pal discussed the emergence of cabozantinib as a treatment option for patients with renal cell carcinoma and touched on future research around the drug.

Sumanta K. Pal, MD, FASCO, spoke with CancerNetwork® regarding the emergence of cabozantinib (Cabometyx) as a treatment option for patients with renal cell carcinoma and discussed future research around the drug from an abstract on the SWOG 1500 trial (NCT02761057) at the 2021 Genitourinary Cancers Symposium.

Transcription:

From here on out, it’s going to be the infrequent patient that receives sunitinib (Sutent) in the frontline setting, outside of perhaps clinical trials. I think that cabozantinib probably should be the gold standard. The big question that emerges is ‘do we combine cabozantinib with immunotherapy now that we can do that for these patients,’ and I would suggest some pause. I would suggest that perhaps it’s better for us to wait until we have randomized data. To that end, we are moving forward with a clinical trial of cabozantinib plus or minus immunotherapy in patients with papillary kidney cancer within the cooperative groups. Once again, it’s a trial…looking at that combination of agents.

Reference:

Pal SK, Tangen C, Thompson IM, et al. Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study. Presented at: 2021 Genitourinary Cancers Symposium. Abstract 270.

Recent Videos
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practice in the breast cancer field.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.
Related Content